CN101766666A - Chinese medicament for treating cardiovascular and cerebrovascular diseases - Google Patents
Chinese medicament for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN101766666A CN101766666A CN200910020880A CN200910020880A CN101766666A CN 101766666 A CN101766666 A CN 101766666A CN 200910020880 A CN200910020880 A CN 200910020880A CN 200910020880 A CN200910020880 A CN 200910020880A CN 101766666 A CN101766666 A CN 101766666A
- Authority
- CN
- China
- Prior art keywords
- panacis quinquefolii
- radix
- radix notoginseng
- radix panacis
- cerebrovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicament for treating cardiovascular and cerebrovascular diseases, which consists of American ginseng and sanchi, wherein a weight ratio of the American ginseng to the sanchi is 1-9:9-1. The American ginseng and the sanchi are micro powders which are subjected to ultramicro wall-breaking crushing. The patent medicine is prepared into 4 grams per bag of soluble granules, or 0.4 grams per capsule of capsules, or 1 gram per tablet of tablets with auxiliary materials. The American ginseng and sanchi soluble granules, capsules or tablets of the invention have good curative effect of treating cardiovascular and cerebrovascular diseases of middle-aged and elderly people, in particular to arteriosclerosis, hypertension, hyperlipemia, heart disease, diabetes mellitus and the like, also can be used as the health care food, have effects of preventing before disease onset, treating disease, preventing thrombosis senescence and eliminating disease and prolonging life and have obvious long term effect and no any side effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine, particularly a kind of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease.
Background technology
At present, the Chinese medicine of treatment cardiovascular and cerebrovascular disease is existing a lot, the capsule or the electuary that wherein have multiple medicinal herb componentses such as containing Radix Panacis Quinquefolii and Radix Notoginseng to be mixed with.Chinese patent publication number CN101073588 discloses " a kind of capsule for the treatment of coronary heart disease ", and its prescription contains Radix Panacis Quinquefolii, Radix Notoginseng, succinum, CUNPU, Radix Et Rhizoma Nardostachyos.Though this medicine has certain therapeutic effect to coronary heart disease, but this medicine has two aspect deficiencies: the one, and prescription is than complexity, the 2nd, because used succinum fusing point is low, easily fusing, To Be Protected from Heat, technological requirement height, difficulty are big in process of manufacture, and contain volatile oil as the Radix Et Rhizoma Nardostachyos of accessory drugs, store improper meeting and cause the effect of medicine to descend.Chinese patent publication number CN1175458 also discloses a kind of " Chinese medicine of treatment cardiovascular and cerebrovascular disease ", it is to be mixed with Chinese medicinal capsule by Radix Panacis Quinquefolii, Radix Sophorae Flavescentis, Radix Notoginseng, Hirudo, its prescription matches with plant, animal drugs and forms, prepare and process also more complicated, and Hirudo is a kind of drug toxicity, regulation for usage and consumption is also quite strict, and this has also increased the difficulty of prescription production and processing to a great extent.
Summary of the invention
The objective of the invention is to overcome deficiencies such as prescription is complicated in the prior art, the production difficulty is big, unstable product quality, provide a kind of prescription simple, produce easily, and evident in efficacy, the course of treatment is shorter, the Chinese medicine of the treatment cardiovascular and cerebrovascular disease of drug quality long-term stability.
The technical scheme that realizes above-mentioned purpose is: a kind of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease, form by Radix Panacis Quinquefolii and Radix Notoginseng, the weight proportion of Radix Panacis Quinquefolii and Radix Notoginseng is 1～9: 9～1, described Radix Panacis Quinquefolii and Radix Notoginseng are the micropowder of ultra micro wall breaking pulverization, patent medicine is the electuary of 4g/ bag, or the capsule of 0.4g/ grain, or be equipped with the tablet of the 1g/ sheet of adjuvant.
Modern medicine thinks that the paathogenic factor of cardiovascular and cerebrovascular diseases such as coronary heart disease has two: the one, and blood essential problem,, blood gruel type sticky, thrombosis etc. as blood; The 2nd, the access issues of blood is as angiostenosis, blood vessel embrittlement etc.Its Therapeutic Principle is for reducing oxygen consumption, and coronary artery dilator improves blood circulation, reduces blood viscosity etc.
Theory of Chinese medical science is thought, Radix Panacis Quinquefolii mildly bitter flavor cool in nature, and GUIXIN lung stomach three warps have the effect of tonifying QI to produce body fluid; Radix Notoginseng property is flat, and sweet-bitter flavor is gone into liver, stomach, large intestine channel, has hemostasis, promoting the circulation of blood, and hemopoietic three big functions, its characteristics do not have the fraud of the stasis of blood of staying for hemostasis, invigorate blood circulation and do not have hemorrhage anxiety, can invigorate blood circulation, hemostasis, analgesic therapy, and stronger tonic effect is arranged.
Modern medicine study confirms, Radix Panacis Quinquefolii is the ginsenoside with the main component of Radix Ginseng, but ginsenoside's lightening heart load, reduce myocardial oxygen consumption, has arrhythmia, resist myocardial ischemia, increase anabolic effect and the anti-stress effect of protein, RNA, DNA, cardiovascular injury is had good protective action; Arasaponin that Radix Notoginseng is contained and pyrite glycoside have tangible coronary artery dilator, strengthen the effect of coronary blood flow quantity, and can reduce myocardial oxygen consumption, strengthen the hypoxia-bearing capability of cardiac muscle.
Radix Panacis Quinquefolii and Radix Notoginseng all have the adjusting microcirculation, improve condition of blood, and can prevent the formation of tampon effectively, strengthen the effect of human body hemopoietic function.They are returned through difference human body, Radix Panacis Quinquefolii GUIXIN, lung, stomach warp; Radix Notoginseng returns liver, stomach, large intestine channel.Two flavor drug matchings make them in the intravital increased functionality of people, and sphere of action enlarges, and whole structure is remarkable.Therefore, Radix Panacis Quinquefolii and Radix Notoginseng two flavor Chinese medicines are that one group of " mutual reinforcement between " property medicine is right, so the pharmaceutical formulation of forming by Radix Panacis Quinquefolii and Radix Notoginseng two flavor Chinese medicines has significant curative effect for treating painstaking effort brain pipe disease.
The Radix Panacis Quinquefolii notoginseng preparations should given birth to usefulness aspect prevention and the treatment cardiovascular and cerebrovascular disease.Giving birth to the characteristic of beating ripe benefit because Radix Notoginseng has, give birth to and use it, can bring into play the effect of its blood circulation promoting and blood stasis dispelling, is the hands section that solves the blood essential problem; Radix Panacis Quinquefolii has the effect of vessel softening, blood vessel dilating, is the important means that solves the blood channel problem.The result that two flavor Chinese medicines play a role jointly is exactly the important measures that solve cardiovascular and cerebrovascular disease.
The present invention carries out the breaking cellular wall micronizing after with Radix Notoginseng and Radix Panacis Quinquefolii compatibility and makes electuary, capsule or tablet, avoided the ripening influence of high temperature extraction on the one hand to Radix Notoginseng, can make the effective ingredient in the medicine can obtain maximum release on the other hand, and two flavor Chinese medicine can Synergistic, the treatment works well.
Practice proves that Radix Panacis Quinquefolii instant notoginseng particles of the present invention, capsule or tablet particularly suffer from treatment of diseases such as arteriosclerosis, hypertension, hyperlipidemia, heart disease, diabetes and have better curative effect for the middle-aged and elderly people cardiovascular and cerebrovascular disease.Also can be used as health food, have the prevention of diseae, ill controlling, the thromboembolism preventing health care, the effect of eliminating disease and prolong life, long-term effect is remarkable, and without any side effect.
The specific embodiment
Below in conjunction with embodiment the present invention is done a nearly step explanation.
Embodiment 1
Soft, section, oven dry below 40 ℃ are made, moistened to Radix Panacis Quinquefolii and Radix Notoginseng only, according to weight ratio: Radix Panacis Quinquefolii: Radix Notoginseng=1: 9 compatibility, mixing, the ultra micro wall breaking pulverization becomes micropowder, is packaged into the electuary (dose of being grown up a time) of 4g/ bag with the powder packets installation; Or become the zero capsule of 0.4g/ grain with the capsule filling machine fill; Or add nearly 30% sorbitol, xylitol or glucose, be pressed into the tablet of 1g/ sheet with tablet machine.This ratio is applicable to blood stasis, thrombosis type cardiovascular and cerebrovascular disease, the effect of outstanding pseudo-ginseng blood-circulation-invigovating blood stasis dispelling.
Embodiment 2
According to the pharmaceutical methods of embodiment 1, the weight ratio of Radix Panacis Quinquefolii and Radix Notoginseng wherein: Radix Panacis Quinquefolii: Radix Notoginseng=2: 8.This ratio is applicable to the cardiovascular and cerebrovascular disease of blood stasis due to qi deficiency, when giving prominence to pseudo-ginseng blood-circulation-invigovating blood stasis dispelling effect, considers the gas compensation function of Radix Panacis Quinquefolii.
Embodiment 3
According to the pharmaceutical methods of embodiment 1, the weight ratio of Radix Panacis Quinquefolii and Radix Notoginseng wherein: Radix Panacis Quinquefolii: Radix Notoginseng=3: 7.This ratio is applicable to blood stasis due to qi deficiency and with the cardiovascular and cerebrovascular disease of angiostenosis, in outstanding pseudo-ginseng blood-circulation-invigovating blood stasis dispelling effect, considers the QI invigorating of Radix Panacis Quinquefolii and the effect of blood vessel dilating.
Embodiment 4
According to the pharmaceutical methods of embodiment 1, the weight ratio of Radix Panacis Quinquefolii and Radix Notoginseng wherein: Radix Panacis Quinquefolii: Radix Notoginseng=6: 6.This ratio is applicable to the cardiovascular and cerebrovascular disease of blood stasis due to qi deficiency, angiostenosis and arteriosclerosis, in outstanding pseudo-ginseng blood-circulation-invigovating blood stasis dispelling effect, fully takes into account the function of QI invigorating, blood vessel dilating and the vessel softening of Radix Panacis Quinquefolii.
Embodiment 5
According to the pharmaceutical methods of embodiment 1, the weight ratio of Radix Panacis Quinquefolii and Radix Notoginseng wherein: Radix Panacis Quinquefolii: Radix Notoginseng=5: 5.This ratio is applicable to the cardiovascular and cerebrovascular disease that blood stasis due to qi deficiency, thrombosis, angiostenosis, arteriosclerosis have concurrently.
The prescription of above-mentioned five kinds of ratios mainly is the blood essential problem that solves in the cardiovascular and cerebrovascular disease, also considers access issues and the two problem that has concurrently of blood simultaneously.
Embodiment 6
According to the pharmaceutical methods of embodiment 1, the weight ratio of Radix Panacis Quinquefolii and Radix Notoginseng wherein: Radix Panacis Quinquefolii: Radix Notoginseng=6: 4.
Embodiment 7
According to the pharmaceutical methods of embodiment 1, the weight ratio of Radix Panacis Quinquefolii and Radix Notoginseng wherein: Radix Panacis Quinquefolii: Radix Notoginseng=7: 3.
Embodiment 8
According to the pharmaceutical methods of embodiment 1, the weight ratio of Radix Panacis Quinquefolii and Radix Notoginseng wherein: Radix Panacis Quinquefolii: Radix Notoginseng=8: 2.
Embodiment 9
According to the pharmaceutical methods of embodiment 1, the weight ratio of Radix Panacis Quinquefolii and Radix Notoginseng wherein: Radix Panacis Quinquefolii: Radix Notoginseng=9: 1.
The prescription of above-mentioned five kinds of ratios mainly is the access issues that solves blood in the cardiovascular and cerebrovascular disease, and considers blood essential problem and the two problem that has concurrently.
Claims (10)
1. Chinese medicine for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that forming by Radix Panacis Quinquefolii and Radix Notoginseng, the weight proportion of Radix Panacis Quinquefolii and Radix Notoginseng is 1～9: 9～1, described Radix Panacis Quinquefolii and Radix Notoginseng are the micropowder of ultra micro wall breaking pulverization, patent medicine is the electuary of 4g/ bag, or the capsule of 0.4g/ grain, or be equipped with the tablet of the 1g/ sheet of adjuvant.
2. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 1: 9.
3. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 2: 8.
4. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 3: 7.
5. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 4: 6.
6. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 5: 5.
7. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 6: 4.
8. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 7: 3.
9. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 8: 2.
10. according to the Chinese medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: the weight proportion of described Radix Panacis Quinquefolii and Radix Notoginseng is 9: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910020880A CN101766666A (en) | 2009-01-07 | 2009-01-07 | Chinese medicament for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910020880A CN101766666A (en) | 2009-01-07 | 2009-01-07 | Chinese medicament for treating cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101766666A true CN101766666A (en) | 2010-07-07 |
Family
ID=42499867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910020880A Pending CN101766666A (en) | 2009-01-07 | 2009-01-07 | Chinese medicament for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101766666A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102599501A (en) * | 2012-03-15 | 2012-07-25 | 宋靖钢 | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver |
| CN103285104A (en) * | 2013-05-14 | 2013-09-11 | 张景红 | Traditional Chinese medicine injection for repairing myocardial injury |
| CN111110734A (en) * | 2020-01-19 | 2020-05-08 | 林金华 | Traditional Chinese medicine composition for treating arteriosclerosis, dosage form and application |
| CN115607630A (en) * | 2020-12-31 | 2023-01-17 | 东莞市德言盛健康产业有限公司 | Traditional Chinese medicine composition with function of reducing blood pressure and preparation method and application thereof |
-
2009
- 2009-01-07 CN CN200910020880A patent/CN101766666A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102599501A (en) * | 2012-03-15 | 2012-07-25 | 宋靖钢 | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver |
| CN102599501B (en) * | 2012-03-15 | 2013-11-06 | 宋靖钢 | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver |
| CN103285104A (en) * | 2013-05-14 | 2013-09-11 | 张景红 | Traditional Chinese medicine injection for repairing myocardial injury |
| CN103285104B (en) * | 2013-05-14 | 2016-01-06 | 张景红 | A kind of have the Chinese medicine injection repairing myocardial damage effect |
| CN111110734A (en) * | 2020-01-19 | 2020-05-08 | 林金华 | Traditional Chinese medicine composition for treating arteriosclerosis, dosage form and application |
| CN115607630A (en) * | 2020-12-31 | 2023-01-17 | 东莞市德言盛健康产业有限公司 | Traditional Chinese medicine composition with function of reducing blood pressure and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104906347B (en) | A kind of gold plum fruit lozenge and preparation method thereof and application | |
| CN101167807B (en) | Traditional Chinese medicine preparation for treating chronic pharyngitis and its preparing process | |
| JP2013532666A (en) | Anti-fatigue composition, its formulation and application | |
| CN101797301B (en) | Medicine for preventing and curing middle and old aged constipation | |
| CN101766666A (en) | Chinese medicament for treating cardiovascular and cerebrovascular diseases | |
| CN101313968A (en) | Pseudo-ginseng dragon's blood preparation | |
| CN102824503A (en) | Concentrated pill for treating atrophic gastritis and strengthening stomach and preparation method thereof | |
| CN102091268A (en) | Medicament for treating allergic rhinitis and preparation method thereof | |
| CN101791332B (en) | Compound gingko health product solid preparation | |
| WO2008119127A1 (en) | Herbal compositions and methods for treating menorrhagia | |
| CN102008623A (en) | Traditional Chinese medicine preparation for treating Meniere's syndrome | |
| CN101669995A (en) | Composite for treatment and health care of heart cerebrovascular diseases and preparation method thereof | |
| CN101564505A (en) | Chinese medicament for treating pulmonary heart disease | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN102366537A (en) | Traditional Chinese medicine preparation for treating cough caused by lung dryness and preparation method thereof | |
| CN113577137B (en) | Traditional Chinese medicine composition for treating acne and preparation method and application thereof | |
| CN101537068B (en) | Chinese medicine for treating angina | |
| CN108477372A (en) | A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar anti-aging tranquilizing effect | |
| CN103417764A (en) | Health care product containing L-carnitine | |
| CN102641413A (en) | Medicine for treating acute enteritis and preparing method thereof | |
| CN102125680A (en) | Anticancer traditional Chinese medicinal composition and use thereof | |
| CN101843660A (en) | Chinese medicament for treating tachycardia | |
| CN100441181C (en) | Method for preparing micropill capsule of salvia miltiorrhiza bge, and gynostemma pentaphyllum, and its use | |
| CN105288107A (en) | Compound hippophae rhamnoides composition for clearing heat from throat and preparation method thereof | |
| CN104666460A (en) | Composition having efficacy of dispelling acnes as well as application and preparation of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100707 |